Case Reports

Isolated splenic metastasis in a patient with two distinct genitourinary malignancies


 

Splenic metastasis is rare, occurring in 2.3%- 7.1% of cases, of which 95% are carcinomas.1 The lung is the most common primary tumor site (21% of cases), followed by the gastrointestinal system, breast, ovaries, and skin. In a retrospective study evaluating the clinical and pathological impact of splenic metastases during a 25-year period in China, it was found that about 5.3% of metastases were isolated splenic metastasis.2 Isolated splenic metastasis from kidney cancer is very rare and is often an incidental finding. Here we report a case with isolated splenic metastasis in a patient with both primary renal cell carcinoma and prostate cancer, which turned out to be metastatic renal cell carcinoma in the spleen.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

ASCO 2015: Dr. Walter M. Stadler gives his top picks in genitourinary research
MDedge Hematology and Oncology
Additive radiotherapy’s advantages outweigh QOL disadvantages
MDedge Hematology and Oncology
VIDEO: Genomic biomarker predicts pembrolizumab response
MDedge Hematology and Oncology
VIDEO: More aggressive treatment with docetaxel boosts survival in prostate cancer
MDedge Hematology and Oncology
VIDEO: Dr. Walter M. Stadler gives take-home messages from ASCO 2015 GU sessions
MDedge Hematology and Oncology
ASCO: Research IDs new subtype of refractory prostate cancer
MDedge Hematology and Oncology
ASCO: Two hits and a miss against advanced urothelial cancer
MDedge Hematology and Oncology
Prostate cancer screening for men over 50 has declined
MDedge Hematology and Oncology
AUA: Renal mass biopsy trend tied to nonsurgical RCC treatment
MDedge Hematology and Oncology
Urine assay ruled out high-grade prostate cancer
MDedge Hematology and Oncology